Nature Reviews Drug Discovery, Published online: 09 November 2026; doi:10.1038/s41573-026-01561-w Histone lysine demethylases regulate gene expression and chromatin structure and help to integrate epigenetics with metabolic and immune responses. This Review discusses the diverse contributions of these demethylases to disease pathogenesis, particularly cancer, and the efforts underway to target them with small molecules.
Amir Hosseini, Yang Shi. Histone lysine demethylases in the third decade: biology and therapeutic prospects. // Nature Reviews Drug Discovery. – 2026. – DOI: 10.1038/s41573-026-01561-w. – URL: https://www.nature.com/articles/s41573-026-01561-w
Amir Hosseini & Yang Shi (2026). Histone lysine demethylases in the third decade: biology and therapeutic prospects. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-026-01561-w
Amir Hosseini and Yang Shi. “Histone lysine demethylases in the third decade: biology and therapeutic prospects.” Nature Reviews Drug Discovery, 2026. doi:10.1038/s41573-026-01561-w.
@article{Hosseini2026,
title = {Histone lysine demethylases in the third decade: biology and therapeutic prospects},
author = {Hosseini, Amir and Shi, Yang},
journal = {Nature Reviews Drug Discovery},
year = {2026},
doi = {10.1038/s41573-026-01561-w},
url = {https://www.nature.com/articles/s41573-026-01561-w}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...